BP-C1(BP-C1) - 药物靶点：DNA_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

DNA

作用机制

DNA抑制剂(DNA抑制剂)、细胞凋亡刺激剂、DNA交联剂

+ [1]

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [1]

在研适应症-

非在研适应症

乳腺癌转移性乳腺癌胰腺癌+ [2]

原研机构

Meabco A/S

在研机构-

非在研机构

Meabco A/S

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

关联

6

项与 BP-C1 相关的临床试验

NCT03627390 / Completed临床2期

The Effect of BP-C1 in Treatment of Inoperable Pancreatic Cancer Patients: A Single Centre Pilot Study

The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.

开始日期2014-12-19

申办/合作机构

Meabco A/S

[+1]

NCT03603197 / Completed临床2期

A Randomized, Double Blind and Placebo Controlled Multicenter Study Comparing BP-C1 and an Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study

The purpose of this study is to determine whether BP-C1 is effective in the short-term treatment of metastatic breast cancer patients who have previously undergone at least three lines of chemotherapy.

开始日期2014-06-05

申办/合作机构

Meabco A/S

[+1]

NCT01861509 / Completed临床1期

Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer. A Phase ID Study

This study is an open label, non-randomized phase I single-armed study in women with metastatic breast cancer (MBC) who have previously undergone all available standard chemotherapy regimens. The purpose of the study is to estimate the pharmacokinetics (PK) after single dose and multiple dose of BP-C1, investigate interleukin levels during BP-C1 treatment and assess treatment response according to RECIST criteria.

开始日期2014-01-19

申办/合作机构

Meabco A/S

100 项与 BP-C1 相关的临床结果

登录后查看更多信息

100 项与 BP-C1 相关的转化医学

登录后查看更多信息

100 项与 BP-C1 相关的专利（医药）

登录后查看更多信息

7

项与 BP-C1 相关的文献（医药）

2022-09-01·Journal of Trace Elements in Medicine and Biology

Assessment of antitumor activity of BP-C1, a platinum-based anticancer agent with a lignin-derived polymeric ligand, in autochthonous induced and spontaneous carcinogenesis rodent models

Article

作者: Anikin, Ivan V ; Panchenko, Andrey V ; Solovyev, Nikolay D ; Tyndyk, Margarita L ; Yurova, Maria N ; Anisimov, Vladimir N ; Pigarev, Sergey E ; Fedoros, Elena I ; Gubareva, Ekaterina A ; Popovich, Irina G

BACKGROUNDA standard approach to study the anticancer activity of novel drugs is their testing in animals with inoculated tumors, which has some limitations. An alternative is the use of spontaneous or carcinogen-induced tumor models as they have better translation potential. The carcinogen-induced and transgenic tumor models were used to assess the antitumor activity of BP-C1, a platinum-containing drug with lignin-derived polymeric ligand.METHODSWe used female Swiss-H-derived mice and Wistar female rats to induce autochthonous tumors via exposure to benzo[a]pyrene and 1,2-dimethylhydrazine, respectively. Additionally, transgenic HER-2/neu FVB/N female mice, prone to the development of spontaneous mammary carcinomas, were used.RESULTSAntitumor activity of BP-C1 was observed in soft tissue sarcomas, induced by benzo[a]pyrene. The animals treated with BP-C1 exhibited more stabilizations and therapy responses compared to placebo controls. The efficacy of BP-C1 was somewhat reduced compared to cyclophosphamide; however, their combination resulted in an enhanced antitumor effect. For the 1,2-dimethylhydrazine-induced rat colon cancer model, BP-C1 reduced tumor multiplicity by 21-41 %. For mammary adenocarcinomas in HER-2/neu FVB/N mice, short-termed complete responses were observed in the BP-C1 groups with a frequency of 12-13 %, while complete responses were absent in the placebo group.CONCLUSIONThe results acquired indicated a wide spectrum of antitumor activity of BP-C1.

2017-11-21·Oncotarget

Results and prospects of development of new polyphenolic drugs for cancer patients

Article

作者: Baldueva, Irina A. ; Perminova, Irina V. ; Scherbakov, Alexander M. ; Larsen, Stig ; Anisimov, Vladimir N. ; Panchenko, Andrey V. ; Nielsen, Tea Kirkegaard ; Drobyshev, Evgeny Yu. ; Fedoros, Elena I. ; Bykov, Vladimir N. ; Malek, Anastasia V. ; Belyaev, Alexey M. ; Lofberg, Stig

The conference "Results and prospects of development of new polyphenolic drugs for cancer patients" took place at the N.N. Petrov National Medical Research Center of Oncology (PNMRCO) on May 31, 2017, and gathered researchers involved in development and evaluation of medicinal products based on the novel lignin-derived soluble polyphenolic polymer BP-Cx-1. BP-Cx-1 is the platform for a portfolio of innovative pharmacological products such as BP-C1, BP-C2 and BP-C3.

PLoS ONE3区 · 综合性期刊

Benzene-Poly-Carboxylic Acid Complex, a Novel Anti-Cancer Agent Induces Apoptosis in Human Breast Cancer Cells

3区 · 综合性期刊

ArticleOA

作者: Fares, Basem ; Lindkaer-Jensen, Steen ; Fares, Fuad ; Azzam, Naiel ; Larsen, Stig

Some cases of breast cancer are composed of clones of hormonal-independent growing cells, which do not respond to therapy. In the present study, the effect of Benzene-Poly-Carboxylic Acid Complex (BP-C1) on growth of human breast-cancer cells was tested. BP-C1 is a novel anti-cancer complex of benzene-poly-carboxylic acids with a very low concentration of cis-diammineplatinum (II) dichloride. Human breast cancer cells, MCF-7 and T47D, were used. Cell viability was detected by XTT assay and apoptosis was detected by Flow Cytometry and by annexin V/FITC/PI assay. Caspases were detected by western blot analysis and gene expression was measured by using the Applied Biosystems® TaqMan® Array Plates. The results showed that exposure of the cells to BP-C1 for 48 h, significantly (P<0.001) reduced cell viability, induced apoptosis and activated caspase 8 and caspace 9. Moreover, gene expression experiments indicated that BP-C1 increased the expression of pro-apoptotic genes (CASP8AP1, TNFRSF21, NFkB2, FADD, BCL10 and CASP8) and lowered the level of mRNA transcripts of inhibitory apoptotic genes (BCL2L11, BCL2L2 and XIAP. These findings may lead to the development of new therapeutic strategies for treatment of human cancer using BP-C1 analog.

100 项与 BP-C1 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除性胰腺癌	临床2期	埃及	Meabco A/S	2014-12-19
胰腺继发性恶性肿瘤	临床2期	埃及	Meabco A/S	2014-12-19
转移性乳腺癌	临床2期	泰国	Meabco A/S	2012-12-24
转移性乳腺癌	临床2期	俄罗斯	Meabco A/S	2012-12-24
乳腺癌	临床2期	挪威	Meabco A/S	2006-08-20
胰腺癌	临床2期	丹麦	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03603197 (Pubmed) 人工标引	临床2期	转移性乳腺癌	31	BP-C1	積膚鬱壓蓋鏇鑰獵襯齋(壓願蓋憲鏇膚鏇鹽構艱) = 鬱範膚遞廠獵蓋遞膚積艱鬱築夢獵窪壓鬱鏇糧 (衊鹽網製築積遞艱範選 ) 更多	积极	2019-01-14
				Placebo	積膚鬱壓蓋鏇鑰獵襯齋(壓願蓋憲鏇膚鏇鹽構艱) = 醖壓顧窪廠鏇鏇齋蓋積艱鬱築夢獵窪壓鬱鏇糧 (衊鹽網製築積遞艱範選 ) 更多
ASCO2017	N/A	不能切除性胰腺癌	12	BP-C1	(繭齋構窪艱構繭鹽網餘) = 顧窪憲鏇壓鏇壓鹽憲選夢鏇築構製製壓壓積壓 (膚窪鏇願鏇範壓醖醖顧, 42.8–94.5) 更多	积极	2017-05-30
ASCO2015	N/A	转移性乳腺癌	30	BP-C1	(簾願製鏇鑰顧窪窪襯製) = few mainly mild AE 顧鏇獵鑰鏇觸範選廠鏇 (壓醖糧鬱壓積選襯夢憲 )	积极	2015-05-20
				Placebo
ASCO2014	N/A	转移性乳腺癌	-	BP-C1	(觸積鑰鏇齋範襯糧顧糧) = Differences in increase in QOL in favor of BP-C1 were detected for all variables 獵餘築鏇選醖壓網觸製 (獵獵範廠觸鏇蓋鏇鏇蓋 )	积极	2014-05-20
				Placebo
ASCO2013	N/A	乳腺癌	-	BP-C1	遞繭艱餘鹹鏇鹹鹹襯繭(醖鏇膚蓋襯築顧壓憲簾) = 繭鏇鹹積蓋糧鹽網繭襯鹹窪鹽憲糧簾壓齋衊醖 (衊鹽窪膚願積範憲積構 )	-	2013-05-20